Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| DMK Pharmaceuticals Corp Com Par $0.001 | APC-8000 (sublingual tadalafil) | Erectile dysfunction | NDA Filing | Sublingual | N/A | |
| DMK Pharmaceuticals Corp Com Par $0.001 | APC-410 (tempol) - (Topical Gel) | Radiation Dermatitis | Phase 2 | Topical | Wound Care | |
| Dogwood Therapeutics Inc. | IMC-1 - (FORTRESS) | Fibromyalgia | Phase 2b | Trial Planned | oral | Neurology |
| Dogwood Therapeutics Inc. | IMC-2 with Valacyclovir and Celecoxib - (Bateman Horne Center trial) | Long COVID-19 | Phase 2 | Enrollment Conclusion | Oral | COVID-19 |
| Dogwood Therapeutics Inc. | Halneuron - (HALT-CINP / HAL-CINP-203) | Chemotherapy-induced Neuropathic Pain | Phase 2b | Data Released | Intravenous | Neurology |
| Dynavax Technologies Corporation | SCB-2019 (CpG 1018/Alum) | COVID-19 vaccine in adolescents | Phase 2/3 | Data Released | Intramuscular | #ERROR: Failed to execute function |
| Dynavax Technologies Corporation | AZD1419 | Asthma | Phase 2a | Trial Discontinued | Inhalation | Respiratory |
| Dynavax Technologies Corporation | CpG 1018 adjuvant with rF1V vaccine - (DoD Trial) | Recombinant plague vaccine | Phase 2 | Ongoing | Intramuscular | N/A |
